dc.contributor
Institut Català de la Salut
dc.contributor
[Elosua-Bayes I, Melgarejo L] Grup de Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Alpuente A, Caronna E, Torres-Ferrús M, Pozo-Rosich P] Grup de Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat de Cefalea i Dolor Neurològic, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Elosua-Bayes, Iker
dc.contributor.author
Alpuente Ruiz, Alicia
dc.contributor.author
Melgarejo Martinez, Laura
dc.contributor.author
Caronna, Edoardo
dc.contributor.author
TORRES-FERRUS, MARTA
dc.contributor.author
Pozo-Rosich, Patricia
dc.date.accessioned
2024-11-01T02:57:43Z
dc.date.available
2024-11-01T02:57:43Z
dc.date.issued
2024-10-31T12:38:33Z
dc.date.issued
2024-10-31T12:38:33Z
dc.identifier
Elosua-Bayes I, Alpuente A, Melgarejo L, Caronna E, Torres-Ferrús M, Pozo-Rosich P. Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data. Cephalalgia. 2024 Sep;44(9):1–6.
dc.identifier
https://hdl.handle.net/11351/12169
dc.identifier
10.1177/03331024241273966
dc.identifier
001328346500009
dc.identifier.uri
http://hdl.handle.net/11351/12169
dc.description.abstract
Adverse drug reaction; Migraine; Pregnancy
dc.description.abstract
Reacción adversa a medicamentos; Migraña; Embarazo
dc.description.abstract
Reacció adversa a medicaments; Migranya; Embaràs
dc.description.abstract
Background
Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP-mAbs) are approved for adult migraine prevention but pose safety concerns in pregnancy. We assess the safety of CGRP-mAbs in the periconceptional period through a case series and literature review.
Methods
Six migraine-diagnosed women received CGRP-mAbs; treatment ceased upon pregnancy. We collected data and conducted safety assessments. To provide a comprehensive context, we performed a literature review.
Results
The series includes three erenumab, two fremanezumab and one galcanezumab case. A fremanezumab recipient experienced miscarriage; severe perinatal asphyxia linked to dystocia occurred with erenumab (140 mg). Database reviews revealed 63 spontaneous abortions, eight premature births, and seven birth defects among 286 World Health Organization and 65 European Medicines Agency cases. These rates align with untreated population rates.
Conclusions
CGRP-mAbs use in the periconceptional period does not lead to clinically significant increase in pregnancy-related pathology or adverse effects on newborns within our case series and the literature reviewed.
dc.format
application/pdf
dc.publisher
SAGE Publications
dc.relation
Cephalalgia;44(9)
dc.relation
https://doi.org/10.1177/03331024241273966
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Migranya - Tractament
dc.subject
Anticossos monoclonals - Ús terapèutic - Efectes secundaris
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized
dc.subject
Other subheadings::Other subheadings::Other subheadings::/adverse effects
dc.subject
DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders
dc.subject
PHENOMENA AND PROCESSES::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproduction::Pregnancy
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Neuropeptides::Calcitonin Gene-Related Peptide
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos
dc.subject
FENÓMENOS Y PROCESOS::fenómenos fisiológicos reproductivos y urinarios::fenómenos fisiológicos de la reproducción::reproducción::embarazo
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::neuropéptidos::péptido relacionado con el gen de calcitonina
dc.title
Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
